Before use, it is necessary to visually assess the vaccine for the presence of foreign impurities or color changes. The vaccine should not be used if any of these conditions are present.
Menactra® vaccine is administered as a single dose of 0.5 ml intramuscularly.
The vaccine is intended for active immunization against meningococcal infection caused by Neisseria meningitidis serogroups A, C, Y and W-135 in persons aged 9 months to 55 years. Menactra® vaccine does not prevent disease caused by N. meningitidis serogroup B.
A severe allergic reaction (eg, anaphylaxis) following a previous dose of vaccine containing meningococcal capsular polysaccharide, diphtheria toxoid, or CRM197 (diphtheria toxoid carrier protein), or to any component of Menactra® vaccine.
Adverse reactions of the body to vaccination include:
Not available